Propranolol concentrations after oral administration in term and preterm neonates

References

• Bruns LA, Canter CE. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? Paediatr Drugs 2002;4:771–8
   PubMedGoogle Scholar
• Fritz KI, Bhat AM. Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. J Perinatol 1998;18:38–44
   PubMedGoogle Scholar
• Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 2006;27:199–203
   PubMed Web of Science ®Google Scholar
• Smith C, Thomsett M, Choong C, et al. Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf) 2001;54:371–6
   PubMedGoogle Scholar
• Mahmoud AB, Tantawy AE, Kouatli AA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg 2008;7:184–7
   PubMedGoogle Scholar
• Garin EH, Araya CE. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr 2009;21:600–4
   PubMedGoogle Scholar
• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649–51
   PubMed Web of Science ®Google Scholar
• Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010;157:340–2
   PubMedGoogle Scholar
• Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011;137:471–8
   PubMedGoogle Scholar
• Missoi TG, Lueder GT, Gilbertson K, Bayliss SJ. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol 2011;129:899–903
   PubMed Web of Science ®Google Scholar
• Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011;75:455–60
   PubMed Web of Science ®Google Scholar
• Chim H, Armijo BS, Miller E, et al. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg 2012;256:146–56
   PubMed Web of Science ®Google Scholar
• Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011;52:155–70
   PubMed Web of Science ®Google Scholar
• Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 2011;119:1317–29
   PubMed Web of Science ®Google Scholar
• Dal Monte M, Martini D, Latina V, et al. Beta-adrenoreceptor (β-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2012;53:2181–92
   PubMed Web of Science ®Google Scholar
• Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with retinopathy of prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010;10:83
   PubMed Web of Science ®Google Scholar
• Leahey WJ, Neill JD, Varma MP, Shanks RG. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol 1980;9:33–40
   PubMed Web of Science ®Google Scholar
• Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. Br J Clin Pharmacol 1984;18:37–43
   PubMedGoogle Scholar
• Serlin MJ, Orme ML, MacIver M, et al. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol 1983;15:519–27
   PubMedGoogle Scholar
• Wójcicki J, Jaroszynska M, Droździk M, et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos 2003;24:211–8
   Google Scholar
• Chidsey CA, Morselli P, Bianchetti G, et al. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 1975;52:313–8
   PubMed Web of Science ®Google Scholar
• Wood AJ, Carr K, Vestal RE, et al. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol 1978;6:345–50
   PubMed Web of Science ®Google Scholar
• Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation 1975;52:6–15
   PubMed Web of Science ®Google Scholar
• la Marca G, Malvagia S, Filippi L, et al. Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J Pharm Biomed Anal 2008;48:1392–6
   PubMed Web of Science ®Google Scholar
• la Marca G, Malvagia S, Filippi L, et al. A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry. Epilepsia 2009;50:2658–62
   PubMed Web of Science ®Google Scholar
• la Marca G, Malvagia S, Filippi L, et al. Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J Pharm Biomed Anal 2011;54:192–7
   PubMedGoogle Scholar
• la Marca G, Giocaliere E, Villanelli F, et al. Development of an UPLC-MS/MS method for the determination of antibiotic ertapenem on dried blood spots. J Pharm Biomed Anal 2012;61:108–13
   PubMed Web of Science ®Google Scholar
• Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009;50:2355–61
   PubMed Web of Science ®Google Scholar
• Filippi L, la Marca G, Cavallaro G, et al. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia 2011;52:794–801
   PubMed Web of Science ®Google Scholar
• Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259–66
   PubMed Web of Science ®Google Scholar
• Przewratil P, Sitkiewicz A, Andrzejewska E. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine 2010;49:141–7
   PubMed Web of Science ®Google Scholar
• Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357–64
   PubMed Web of Science ®Google Scholar
• Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005;97:1182–9
   PubMed Web of Science ®Google Scholar
• Annabi B, Lachambre MP, Plouffe K, et al. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009;60:438–45
   PubMedGoogle Scholar
• Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298–304
   PubMed Web of Science ®Google Scholar
• Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133–40
   PubMedGoogle Scholar
• Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 2009;123:e484–9
   PubMedGoogle Scholar
• Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008;153:712–5
   PubMed Web of Science ®Google Scholar
• Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003;55:667–86
   PubMed Web of Science ®Google Scholar
• Koren G. Therapeutic drug monitoring principles in the neonate. Natl Acad Clin Biochem Clin Chem 1997;43:222–7
   Google Scholar
• Wilson JT, Atwood GF, Shand DG. Disposition of propoxyphene and propranolol in children. Clin Pharmacol Ther 1976;19:264–70
   PubMedGoogle Scholar
• Ponce FE, Williams LC, Webb HM, et al. Propranolol palliation of tetralogy of Fallot: experience with long-term drug treatment in pediatric patients. Pediatrics 1973;52:100–8
   PubMedGoogle Scholar
• Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci 1971;60:1338–40
   PubMed Web of Science ®Google Scholar
• Shand DG, Sell CG, Oates JA. Hypertrophic obstructive cardiomyopathy in an infant – propranolol therapy for three years. N Engl J Med 1971;285:843–4
   PubMedGoogle Scholar
• Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257–63
   Google Scholar
• Sowinski KM, Lima JJ, Burlew BS, et al. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996;42:339–46
   PubMedGoogle Scholar